MBX Biosciences, Inc. (MBX)
NMS · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
MBX Biosciences Lacks Substantive Content in Year-End Report
***Due to the lack of substantive content within the provided PDF attachment, I cannot perform a detailed financial and strategic analysis. The filing metadata only confirms the type (ARS) and the reporting period (Year-End 2025) but contains no text, tables, or narrative information to summarize.**
MBX Biosciences details annual meeting votes for directors and auditors
# 📜 What This Document Is 🗓️ This document is a Definitive Proxy Statement (DEF 14A), which is essentially a mandatory, detailed rulebook for the upcoming Annual Meeting of Stockholders. Think of it as a comprehensive guidebook that tells you exactly *why* the company needs to meet, *who* is runni
SEC filings
All filings →Insider trades
All insider trades →MBX Biosciences, Inc. has no reported insider trades in the last 90 days.